Managing urinary incontinence in women - a review of new and emerging pharmacotherapy

Riccardo Bientinesi, Emilio Sacco

Research output: Contribution to journalArticle

2 Citations (Scopus)


Introduction: The pharmacological treatment of urinary incontinence and overactive bladder (OAB) has been, for a longer time, based on antimuscarinic agents. In recent years, two other pharmacological principles have been introduced for the treatment of OAB and urgency urinary incontinence: the β3-adrenergic agent mirabegron and botulinum neurotoxin. Meanwhile, there is lack of effective drugs for the treatment of stress incontinence. Areas covered: This literature review presents synthetic compounds aimed to treat female urinary incontinence that are in phase II-III clinical development. Expert opinion: Antimuscarinic agents will continue to represent the current gold standard for the first-line pharmacological management of OAB and urgency urinary incontinence. The class of β3-agonists will certainly expand with the discovery and clinical development of novel agents. Combination therapy of antimuscarinic agents and β3-agonists could offer an alternative treatment in these patients, including those with symptoms refractory to first-line monotherapy. A huge number of preclinical studies are underway in this field exploring the therapeutic potential of many novel compounds while some have advanced to clinical phases of development.
Original languageEnglish
Pages (from-to)1989-1997
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Publication statusPublished - 2018


  • Adrenergic beta-3 Receptor Agonists
  • Female
  • Humans
  • Middle Aged
  • Muscarinic Antagonists
  • Pharmacological therapy
  • Urinary Incontinence
  • female urinary incontinence
  • overactive bladder
  • urinary incontinence


Dive into the research topics of 'Managing urinary incontinence in women - a review of new and emerging pharmacotherapy'. Together they form a unique fingerprint.

Cite this